Opinion

Video

Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Jamie L. Koprivnikar, MD

The panelists provide their final thoughts, highlighting financial considerations in PNH treatment.

Video content above is prompted by the following question:

  • How do financial considerations influence your treatment decision-making process?
Related Videos
Mohit Narang, MD
Craig A. Portell, MD, UVA Health
5 experts in this video
5 experts in this video
Pieter Sonneveld, MD, PhD
Related Content
Other AF prediction models have been proposed, including one with a machine-learning approach, but earlier models may not apply to patients taking second-generation BTKis. | Image Credit: sovova - stock.adobe.com
May 15th 2025

Novel AI-Based Score Could Pinpoint AF Risk in Patients With CLL on BTKis

Jared Kaltwasser
A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).
Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH
July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

A trio of experts discuss the challenges of diagnosing and managing paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening disorder.
While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com
May 1st 2025

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

AJMC Contributor
Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).
Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News
September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
The investigators found that people with MPNs and at least one CVRF had an increased risk of both death and arterial or venous thrombosis. | Image credit: Dr_Microbe - stock.adobe.com
April 21st 2025

Cardiovascular Risk Factors Impact Outcomes in MPNs

Jared Kaltwasser
Cardiovascular risk factors increase the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms, a study found.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo